{"id":508141,"date":"2021-06-30T08:03:54","date_gmt":"2021-06-30T12:03:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"modified":"2021-06-30T08:03:54","modified_gmt":"2021-06-30T12:03:54","slug":"cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","title":{"rendered":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, June  30, 2021  (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31<sup>st<\/sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.<\/p>\n<p>Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in\u00a0critically\u00a0ill\u00a0and cancer patients.<\/p>\n<p>\n        <strong>Abstracts selected for presentation are summarized below. <\/strong>\n      <\/p>\n<p>\n        <strong>Oral Presentation: <\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and\/or Invasive Candidiasis: Outcomes During Initial Days of Treatment <br \/><strong>Presenter:<\/strong> Alex Soriano, M.D., Ph.D., University of Barcelona <br \/><strong>Session Date\/Time:<\/strong> Saturday, July 10, 2021 at 7:55 p.m. ET<\/p>\n<p>\n        <strong>On-Demand e-Poster Presentations:<\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween<sup>\u00ae<\/sup>20<br \/><strong>Presenter:<\/strong> Jeffrey B Locke, Ph.D., Cidara<\/p>\n<ul type=\"disc\">\n<li>Selected for e-Poster review session, <em>Antifungal drug resistance and beyond, <\/em>on Sunday, July 11, 2021 from 9:30-10:00 a.m. ET<\/li>\n<\/ul>\n<p>\n        <strong>Title:<\/strong> Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and\/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values<br \/><strong>Presenter:<\/strong> George R. Thompson III, M.D., University of California Davis Medical Center, Davis<\/p>\n<p>\n        <strong>Title:<\/strong> A Multicenter Pharmacoepidemiologic Evaluation of Echinocandin Use<br \/><strong>Presenter:<\/strong> Jinhee Jo, Pharm.D., University of Houston<\/p>\n<p>To register and view the full schedule, visit ECCMID 2021\u2019s website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C_vdriyakdyQHBfdydoZe0gOspEDS89734bn1LeZPZ_CCK-0dQoWVgSMxGwi5USRorY7JxgzDqlLByoXttf0Qg==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Copies of the presentations will be made available on the Publications section of Cidara\u2019s website.<\/p>\n<p>\n        <strong>About Rezafungin<\/strong><br \/>\n        <br \/>Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and\/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).<\/p>\n<p>\n        <strong>About Cidara Therapeutics<\/strong><br \/>\n        <br \/>Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company\u2019s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara\u2019s proprietary Cloudbreak<sup>\u00ae<\/sup> antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y-SZGkDNAaI_L6HoiM7JkdHMiACL2WUzaQZptrn5sF6nKGcwOE8yU4VpLItNWsgvN-h8ShYIl_j3LQTa38uU_g==\" rel=\"nofollow noopener\" target=\"_blank\">www.cidara.com<\/a>.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/>britchie@lifesciadvisors.com<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Patrick Bursey<br \/>LifeSci Communications<br \/>(203) 430-9545<br \/>pbursey@lifescicomms.com<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/51eacace-942f-4a81-bc19-9ba04bd02604\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in\u00a0critically\u00a0ill\u00a0and cancer patients. Abstracts selected for presentation are summarized below. Oral Presentation: Title: Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and\/or Invasive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508141","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in\u00a0critically\u00a0ill\u00a0and cancer patients. Abstracts selected for presentation are summarized below. Oral Presentation: Title: Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and\/or Invasive &hellip; Continue reading &quot;Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-30T12:03:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)\",\"datePublished\":\"2021-06-30T12:03:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"},\"wordCount\":489,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\",\"name\":\"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\",\"datePublished\":\"2021-06-30T12:03:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk","og_description":"SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in\u00a0critically\u00a0ill\u00a0and cancer patients. Abstracts selected for presentation are summarized below. Oral Presentation: Title: Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and\/or Invasive &hellip; Continue reading \"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-30T12:03:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","datePublished":"2021-06-30T12:03:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"wordCount":489,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","name":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=","datePublished":"2021-06-30T12:03:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY4OSM0MjcyNzA3IzIwMTczOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-present-new-analyses-for-rezafungin-at-the-31st-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508141"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508141\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}